Cyclooxygenase-2, Prostaglandin E2, and Microglial Activation in Prion Diseases

International Review of Neurobiology

Volumn 82, Issue , 2007, Pages 265-275

  Minghetti, Luisa ^a   Pocchiari, Maurizio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN E2;

ANIMAL; BRAIN; HUMAN; MICROGLIA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRION DISEASE; REVIEW;

ANIMALS; BRAIN; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; MICROGLIA; PRION DISEASES;

EID: 34547263566     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(07)82014-9     Document Type: Review

References (48)

1. Baker C.A., Lu Z.Y., Zaitsev I., and Manuelidis L. Microglial activation varies in different models of Creutzfeldt-Jakob disease. J. Virol. 73 (1999) 5089-5097
2. Bate C., Rutherford S., Gravenor M., Reid S., and Williams A. Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro. Neuroreport 13 (2002) 1933-1938
3. Bazan N.G. Synaptic lipid signaling: Significance of polyunsaturated fatty acids and platelet-activating factor. J. Lipid Res. 44 (2003) 2221-2233
4. Betmouni S., Perry V.H., and Gordon J.L. Evidence for an early inflammatory response in the central nervous system of mice with scrapie. Neuroscience 74 (1996) 1-5
5. Blais V., Turrin N.P., and Rivest S. Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli. J. Neurochem. 95 (2005) 1563-1574
6. 2. J. Neurochem. 91 (2004) 1389-1397
7. Breder C.D., Dewitt D., and Kraig R.P. Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. 355 (1995) 296-315
8. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., and Simmons D.L. COX-3, a cycloxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure and expression. Proc. Natl. Acad. Sci. USA 99 (2002) 13926-13931
9. 2 signaling in hippocampal long-term synaptic activity. J. Neurophysiol. 87 (2002) 2851-2857
10. 2, cognitive decline, and survival in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 77 (2006) 85-88
11. De Simone R., Ajmone-Cat M.A., and Minghetti L. Atypical antiinflammatory activation of microglia induced by apoptotic neurons: Possible role of phosphatidylserine-phosphatidylserine receptor interaction. Mol. Neurobiol. 29 (2004) 197-212
12. Ek M., Engblom D., Saha S., Blomqvist A., Jakobsson P., and Ericsson-Dahlstrand A. Inflammatory response: Pathway across the blood-brain barrier. Nature 410 (2001) 430-431
13. Firuzi O., and Pratico D. Coxibs and Alzheimer's disease: Should they stay or should they go?. Ann. Neurol. 59 (2006) 219-228
14. Funk C.D. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294 (2001) 1871-1875
15. Gray F., Chretien F., Adle-Biassette H., Dorandeu A., Ereau T., Delisle M.B., Kopp N., Ironside J.W., and Vital C. Neuronal apoptosis in Creutzfeldt-Jakob disease. J. Neuropathol. Exp. Neurol. 58 (1999) 321-328
16. Guenther K., Deacon R.M., Perry V.H., and Rawlins J.N. Early behavioural changes in scrapie-affected mice and the influence of dapsone. Eur. J. Neurosci. 14 (2001) 401-409
17. Harris S.G., Padilla J., Koumas L., Ray D., and Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol. 23 (2002) 144-150
18. Hewitt P.E., Llewelyn C.A., Mackenzie J., and Will R.G. Creutzfeldt-Jakob disease and blood transfusion: Results of the UK transfusion medicine epidemiological review study. Vox Sang. 91 (2006) 221-230
19. Hoozemans J.J., Veerhuis R., Rozemuller A.J., Arendt T., and Eikelenboom P. Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. Neurobiol. Dis. 15 (2004) 492-499
20. Hoozemans J.J., van Haastert E.S., Veerhuis R., Arendt T., Scheper W., Eikelenboom P., and Rozemuller A.J. Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. J. Neuroinflammation 2 (2005) 27
21. Ironside J.W., Ritchie D.L., and Head M.W. Phenotypic variability in human prion diseases. Neuropathol. Appl. Neurobiol. 31 (2005) 565-579
22. Kaufmann W.E., Worley P.F., Pegg J., Bremer M., and Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. USA 93 (1996) 2317-2321
23. Kaufmann W.E., Worley P.F., Taylor C.V., Bremer M., and Isakson P.C. Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome. Brain Dev. 19 (1997) 25-34
24. Kis B., Snipes J.A., and Busija D.W. Acetaminophen and the cyclooxygenase-3 puzzle: Sorting out facts, fictions, and uncertainties. J. Pharmacol. Exp. Ther. 315 (2005) 1-7
25. Levi G., Minghetti L., and Aloisi F. Regulation of prostanoid synthesis in microglial cells and effects of prostaglandin E2 on microglial functions. Biochimie 80 (1999) 899-904
26. Manuelidis L., Fritch W., and Zaitsev I. Dapsone to delay symptoms in Creutzfeldt-Jakob disease. Lancet 352 (1998) 456
27. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63 (2004) 901-910
28. 2-isoprostane in human and experimental transmissible spongiform encephalopathies. J. Neuropathol. Exp. Neurol. 59 (2000) 866-871
29. Minghetti L., Cardone F., Greco A., Puopolo M., Levi G., Green A.J., Knight R., and Pocchiari M. Increased CSF levels of prostaglandin E(2) in variant Creutzfeldt-Jakob disease. Neurology 58 (2002) 127-129
30. Minghetti L., Sbriccoli M., Geloso M.C., Ingrosso L., Di Bari M.A., Greco A., Cardone F., and Pocchiari M. Cyclooxygenases and prostaglandin E2 in animal and human prion diseases. Proceedings VII European Meeting on glial cell functions, 2005 May 17-21, Amsterdam (2005), Medimond International Proceeding Publishers
31. Parchi P., Giese A., Capellari S., Brown P., Schulz-Schaeffer W., Windl O., Zerr I., Budka H., Kopp N., Piccardo P., Poser S., Rojiani A., et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann. Neurol. 46 (1999) 224-233
32. Perry V.H., Cunningham C., and Boche D. Atypical inflammation in the central nervous system in prion disease. Curr. Opin. Neurol. 15 (2002) 349-354
33. Pocchiari M., Puopolo M., Croes E.A., Budka H., Gelpi E., Collins S., Lewis V., Sutcliffe T., Guilivi A., Delasnerie-Laupretre N., Brandel J.P., Alperovitch A., et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 127 (2004) 2348-2359
34. Psaty B.M., and Furberg C.D. COX-2 inhibitors: Lessons in drug safety. N. Engl. J. Med. 352 (2005) 1133-1135
35. Puoti G., Giaccone G., Mangieri M., Limido L., Fociani P., Zerbi P., Suardi S., Rossi G., Iussich S., Capobianco R., Di Fede G., Marcon G., et al. Sporadic Creutzfeldt-Jakob disease: The extent of microglia activation is dependent on the biochemical type of PrPSc. J. Neuropathol. Exp. Neurol. 64 (2005) 902-909
36. Qin N., Zhang S.P., Reitz T.L., Mei J.M., and Flores C.M. Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: Evidence for intron 1 retention. J. Pharmacol. Exp. Ther. 315 (2005) 1298-1305
37. Rall J.M., Mach S.A., and Dash P.K. Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats. Brain Res. 968 (2003) 273-276
38. Ricceri L., Minghetti L., Moles A., Popoli P., Confaloni A., De Simone R., Piscopo P., Scattoni M.L., di Luca M., and Calamandrei G. Cognitive and neurological deficits induced by early and prolonged basal forebrain cholinergic hypofunction in rats. Exp. Neurol. 189 (2004) 162-172
39. Sang N., Zhang J., Marcheselli V., Bazan N.G., and Chen C. Postsynaptically synthesized prostaglandin E2 (PGE2) modulates hippocampal synaptic transmission via a presynaptic PGE2 EP2 receptor. J. Neurosci. 25 (2005) 9858-9870
40. Sharifzadeh M., Naghdi N., Khosrovani S., Ostad S.N., Sharifzadeh K., and Roghani A. Post-training intrahippocampal infusion of the COX-2 inhibitor celecoxib impaired spatial memory retention in rats. Eur. J. Pharmacol. 511 (2005) 159-166
41. Shie F.S., Breyer R.M., and Montine T.J. Microglia lacking E prostanoid receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am. J. Pathol. 166 (2005) 1163-1172
42. Smith W.L., Garavito R.M., and DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271 (1996) 33157-33160
43. Teather L.A., Packard M.G., and Bazan N.G. Post-training cyclooxygenase-2 (COX-2) inhibition impairs memory consolidation. Learn. Mem. 9 (2002) 41-47
44. Vazquez-Tello A., Fan L., Hou X., Joyal J.S., Mancini J.A., Quiniou C., Clyman R.I., Gobeil Jr. F., Varma D.R., and Chemtob S. Intracellular-specific colocalization of prostaglandin E2 synthases and cyclooxygenases in the brain. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287 (2004) R1155-R1163
45. Walsh D.T., Perry V.H., and Minghetti L. Cyclooxygenase-2 is highly expressed in microglial-like cells in a murine model of prion disease. Glia 29 (2000) 392-396
46. Will R.G., Ironside J.W., Zeidler M., Cousens S.N., Esstibeiro K., Alperovitch A., Poser S., Pocchiari M., Hofman A., and Smith P.G. A new variant Creutzfeldt-Jakob disease in the UK. Lancet 347 (1996) 921-925
47. Will R.G., Alperovitch A., Poser S., Pocchiari M., Hofman A., Mitrova E., de Silva R., D'Alessandro M., Delasnerie-Laupretre N., Zerr I., and van Duijn C. Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. EU Collaborative Study Group for CJD. Ann. Neurol. 43 (1998) 763-767
48. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830 (1999) 226-236